谷氨酸的一种运动反应代谢物对胰岛素信号传递的影响
Xiaorui Xing1, Qin Sun1, Ruwen Wang1
1School of Exercise and Health, Shanghai University of Sport, Shanghai 200438, China.
Life sciences
|February 1, 2024
概括
循环中的谷氨酸含量升高与胰岛素抵抗和代谢疾病有关. 运动可以通过降低谷氨酸水平来改善胰岛素敏感性,这表明谷氨酸酸.
科学领域:
- 代谢生理学 代谢生理学
- 内分泌学 在内分泌学.
- 生物化学 生物化学
背景情况:
- 胰岛素抵抗 (IR) 破坏葡萄糖和脂质的新陈代谢.
- 循环中的高谷氨酸与代谢功能障碍相关,可以预测代谢疾病.
- 谷氨酸受体对抗剂可以改善胰岛素敏感性和代谢概况.
研究的目的:
- 审查关于谷氨酸,IR和代谢疾病的临床前和临床数据.
- 讨论过多的谷氨酸在IR和代谢障碍中的作用.
- 为了概述运动诱导的循环谷氨酸的变化.
主要方法:
- 在PubMed数据库 (1955-2024) 中进行了全面的文献搜索.
- 关键词:谷氨酸,谷氨酸酸,胰岛素信号传递,胰岛素抵抗,胰岛素敏感性,运动,身体活动.
主要成果:
- 循环中的谷氨酸水平与IR正相关.
- 过多的谷氨酸会通过脂质积累,炎症和ER压力损害胰岛素信号传递.
- 谷氨酸会影响线粒体功能和 purin 降解.
- 运动可以通过增强代谢和吸收来降低循环中的谷氨酸.
结论:
- 谷氨酸可能会调解运动诱导的胰岛素敏感性改善.
相关概念视频
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
Hormones Regulating Blood Glucose
3.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.4K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Glucagon-like Receptor Agonists
323
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
323
Insulin Secretory Vesicles
5.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.0K
Dipeptidyl Peptidase 4 Inhibitors
187
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
187


